Multi-targeted benzylpiperidine–isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies
Journal of Computer-Aided Molecular Design · 2025
DOI: 10.1007/s10822-025-00588-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Computer-Aided Molecular Design, 2025. Verfasst von Nikita Negi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Cholinesterase Inhibitors, Piperidines, Monoamine Oxidase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: University Grants Commission.
Abstract (Originalsprache)
Neurodegenerative diseases (NDDs) like Alzheimer's and Parkinson's, characterized by gradual loss of neuronal structure and function, results in cognitive and motor impairments. These complex disorders involve multiple pathogenic mechanisms, including neurotransmitter imbalances, oxidative stress, and protein misfolding, necessitating multifunctional therapeutic approaches. Piperidine and isatin are valuable scaffolds in drug design due to their favorable pharmacokinetic profiles, ability to cross blood-brain barrier, and ease of modification. This study focuses on design, synthesis, and evaluation of benzylpiperidine-isatin hybrids as dual inhibitors targeting key enzymes implicated in NDDs: monoamine oxidases (MAO-A/B) and acetylcholinesterase (AChE). Strategic hybridization of piperidine and isatin produced novel benzylpiperidine-isatin hybrids, combining pharmacological benefits of both scaffolds. Synthesized hybrids were tested for MAO-A/B and AChE inhibitory effects. 15 emerged as a lead inhibitor for both MAO-A (IC50 = 0.108 ± 0.004 μM, competitive and reversible) and AChE (IC50 = 0.034 ± 0.002 μM, mixed and reversible), outperforming donepezil in AChE inhibition. 4 showed significant MAO-B inhibition (IC50 = 0.057 ± 0.001 μM, competitive and reversible). SAR studies identified crucial structural elements for potency and selectivity, while molecular docking revealed key interactions stabilizing the enzyme-inhibitor complexes. MD simulations of lead molecules demonstrate the ligand's suitability for strong and consistent binding to the respective proteins. Lead compounds were non-neurotoxic, exhibited good antioxidant properties, and had favorable in silico ADMET predictions. These findings suggest that benzylpiperidine-isatin hybrids hold promise as multifunctional agents against NDDs, warranting further refinement to enhance their efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India.
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221005, India.
- Department of Pharmaceutical Sciences, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, 788011, India. rati.tripathi.phe09@iitbhu.ac.in.
ORCID-Profile: Rati K P Tripathi
Förderung
- University Grants Commission
Zitieren
APA
Negi, N., Ayyannan, S. R., & Tripathi, R. K. P. (2025). Multi-targeted benzylpiperidine–isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies. Journal of Computer-Aided Molecular Design. https://doi.org/10.1007/s10822-025-00588-2
Vancouver
Negi N, Ayyannan SR, Tripathi RKP. Multi-targeted benzylpiperidine–isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies. Journal of Computer-Aided Molecular Design. 2025. doi:10.1007/s10822-025-00588-2
BibTeX
@article{Negi2025,
author = {Negi, Nikita and Ayyannan, Senthil R and Tripathi, Rati K P},
title = {Multi-targeted benzylpiperidine–isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies},
journal = {Journal of Computer-Aided Molecular Design},
year = {2025},
doi = {10.1007/s10822-025-00588-2}
}
EUVIMED